Abstract
The emergence of biosimilar products has resulted in hopes of significant cost savings on biologic therapies. While previous work has analyzed generic competition in small molecule products, there is limited empirical knowledge of the impact of biosimilar entry on the extensive margin (utilization of drugs by patients) as well as the intensive margin (impact on unit prices). We study various measures of social welfare gain from biosimilar entry in the basal insulin market in the United States.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
